一氧化二氮/氧气固定混合气体减轻皮下注射所致疼痛:随机对照试验研究方案
该单中心随机双盲安慰剂对照试验在深圳大学总医院血液肿瘤科开展,纳入54例需皮下注射重组人粒细胞集落刺激因子的血液恶性肿瘤患者,按2:1随机分入一氧化二氮/氧气固定混合气体组(n=36)或氧气组(n=18),主要结局为皮下注射期间最高疼痛数字评定量表评分,以评估该混合气体的安全性与镇痛效果。
要点
- 单中心随机双盲安慰剂对照试验,纳入54例需皮下注射重组人粒细胞集落刺激因子的血液恶性肿瘤患者。
- 一氧化二氮/氧气固定混合气体组36例,氧气组18例,于基线、注射即刻及注射后5分钟监测结局。
- 主要结局为注射期间最高疼痛数字评定量表评分,次要结局包括恐惧、焦虑、生理参数、不良反应及满意度等。
核心结论
- 该研究聚焦皮下注射重组人粒细胞集落刺激因子过程中的安全性与镇痛效果,若证明对血液恶性肿瘤患者有益,将提供一氧化二氮/氧气疗法的可行性与安全性数据,并可在该科室的程序性疼痛患者中广泛使用。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照试验,在深圳大学总医院血液肿瘤科开展。
- 共54例符合条件的需皮下注射重组人粒细胞集落刺激因子的血液恶性肿瘤患者,随机分配至一氧化二氮/氧气固定混合气体组(n=36)或氧气组(n=18)。
- 研究者和患者均不知晓随机化列表及每个气瓶内气体的性质。
- 于基线(T0)、皮下注射重组人粒细胞集落刺激因子后即刻(T1)及注射后5分钟(T2)监测结局。
主要发现
- 主要结局指标为皮下注射重组人粒细胞集落刺激因子期间最高疼痛水平对应的数字评定量表评分。
- 次要结局包括对疼痛的恐惧、焦虑评分、四项生理参数、不良反应、气体给药总时间、患者与护士的满意度及患者的接受度。
关键数值与推荐
- 中文临床试验注册中心注册号ChiCTR2200061507,注册日期2022年6月27日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with hematological malignancies received multiple hypodermic injections of recombinant human granulocyte colony-stimulating factor. Procedural pain is one of the most common iatrogenic causes of pain in patients with hematological malignancies. It is also identified as the most commonly occurring problem in clinical care in the Department of Hematology and Oncology at Shenzhen University General Hospital. However, providing immediate relief from pain induced by hypodermic injection of recombinant human granulocyte colony-stimulating factor remains a major challenge. This trial aims to evaluate the safety and analgesic efficacy of a fixed nitrous oxide/oxygen mixture for patients with hematological malignancies and experiencing procedural pain caused by hypodermic injection of recombinant human granulocyte colony-stimulating factor in the department. METHODS: The nitrous oxide/oxygen study is a single-center, randomized, double-blind, placebo-controlled trial involving patients with hematological malignancies who require hypodermic injections of recombinant human granulocyte colony-stimulating factor for treatment. This trial was conducted in the Hematology and Oncology Department of Shenzhen University General Hospital. A total of 54 eligible patients were randomly allocated to either the fixed nitrous oxide/oxygen mixture group (n = 36) or the oxygen group (n = 18). Neither the investigators nor the patients known about the randomization list and the nature of the gas mixture in each cylinder. Outcomes were monitored at the baseline (T0), immediately after hypodermic injection of recombinant human granulocyte colony-stimulating factor (T1), and 5 min after hypodermic injection of recombinant human granulocyte colony-stimulating factor (T2) for each group. The primary outcome measure was the score in the numerical rating scale corresponding to the highest level of pain experienced during hypodermic injection of recombinant human granulocyte colony-stimulating factor. Secondary outcomes included the fear of pain, anxiety score, four physiological parameters, adverse effects, total time of gas administration, satisfaction from both patients and nurses, and the acceptance of the patients. DISCUSSION: This study focused on the safety and analgesic efficacy during hypodermic injection of recombinant human granulocyte colony-stimulating factor procedure. Data on the feasibility and safety of nitrous oxide/oxygen therapy was provided if proven beneficial to patients with hematological malignancies during hypodermic injection of recombinant human granulocyte colony-stimulating factor and widely administered to patients with procedural pain in the department. TRIAL REGISTRATION: Chinese Clinical Trial Register, ChiCTR2200061507. Registered on June 27, 2022. http://www.chictr.org.cn/edit.aspx?pid=170573&htm=4.
引用
- Zhang JJ, Yu P, Dang H, et al. A nitrous oxide/oxygen fixed mixture to reduce pain induced by the hypodermic injection: study protocol for a randomized, controlled trial. Trials. 2024. PMID: 38218944. doi:10.1186/s13063-024-07919-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。